JP2024530839A - サポニン、オリゴヌクレオチド、およびGalNAcの複合体 - Google Patents
サポニン、オリゴヌクレオチド、およびGalNAcの複合体 Download PDFInfo
- Publication number
- JP2024530839A JP2024530839A JP2023578030A JP2023578030A JP2024530839A JP 2024530839 A JP2024530839 A JP 2024530839A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2023578030 A JP2023578030 A JP 2023578030A JP 2024530839 A JP2024530839 A JP 2024530839A
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- oligonucleotide
- molecule
- galnac
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2021/050384 WO2021261992A1 (en) | 2020-06-24 | 2021-06-18 | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate |
| NLPCT/NL2021/050384 | 2021-06-18 | ||
| NLPCT/NL2021/050549 | 2021-09-09 | ||
| PCT/NL2021/050549 WO2022055351A1 (en) | 2020-09-10 | 2021-09-09 | Conjugate of saponin, oligonucleotide and galnac |
| PCT/NL2022/050127 WO2022265493A1 (en) | 2021-06-18 | 2022-03-08 | Conjugate of saponin, oligonucleotide and galnac |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024530839A true JP2024530839A (ja) | 2024-08-26 |
| JP2024530839A5 JP2024530839A5 (cg-RX-API-DMAC10.html) | 2025-03-13 |
Family
ID=80785160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578030A Pending JP2024530839A (ja) | 2021-06-18 | 2022-03-08 | サポニン、オリゴヌクレオチド、およびGalNAcの複合体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240307545A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4591938A3 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024530839A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022265493A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118356506A (zh) * | 2023-01-17 | 2024-07-19 | 中国科学院上海药物研究所 | 去唾液酸糖蛋白受体配体与细胞毒素的偶联物及其应用 |
| GB202300865D0 (en) * | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024235273A1 (zh) * | 2023-05-15 | 2024-11-21 | 成都社泰医疗科技有限公司 | 多靶向化合物及其应用 |
| JP2026521777A (ja) * | 2023-06-21 | 2026-07-01 | サプリーム テクノロジーズ,ベー.フェー. | 中枢神経系障害を処置するための医薬組成物 |
| WO2026087680A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for cardiovascular disease |
| WO2026087695A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for metabolic disorder |
| WO2026087678A1 (en) | 2024-10-24 | 2026-04-30 | Sapreme Technologies B.V. | Treatment for renal disorders |
| WO2026119464A1 (en) | 2024-12-03 | 2026-06-11 | Sapreme Technologies B.V. | Treatment for cns-related disease |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07509440A (ja) * | 1992-07-02 | 1995-10-19 | ケンブリッジ・バイオテック・コーポレイション | 変性サポニンによる薬物送達促進方法 |
| US20040242502A1 (en) * | 2003-04-08 | 2004-12-02 | Galenica Pharmaceuticals, Inc. | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines |
| WO2019011914A1 (en) * | 2017-07-11 | 2019-01-17 | Freie Universität Berlin | NOVEL USES OF SAPONIN AND METHOD FOR ITS ISOLATION |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011054811A1 (en) * | 2009-11-03 | 2011-05-12 | Santaris Pharma A/S | Rna antagonists targeting hsp27 combination therapy |
| KR20160083876A (ko) * | 2013-11-14 | 2016-07-12 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | ApoB 안티센스 접합체 화합물 |
| US20220023433A1 (en) * | 2018-12-21 | 2022-01-27 | Sapreme Technologies B.V. | Saponin Conjugates |
| WO2022055351A1 (en) * | 2020-09-10 | 2022-03-17 | Sapreme Technologies B.V. | Conjugate of saponin, oligonucleotide and galnac |
-
2022
- 2022-03-08 WO PCT/NL2022/050127 patent/WO2022265493A1/en not_active Ceased
- 2022-03-08 EP EP25177636.5A patent/EP4591938A3/en active Pending
- 2022-03-08 JP JP2023578030A patent/JP2024530839A/ja active Pending
- 2022-03-08 US US18/571,599 patent/US20240307545A1/en active Pending
- 2022-03-08 EP EP22711105.1A patent/EP4355369B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07509440A (ja) * | 1992-07-02 | 1995-10-19 | ケンブリッジ・バイオテック・コーポレイション | 変性サポニンによる薬物送達促進方法 |
| US20040242502A1 (en) * | 2003-04-08 | 2004-12-02 | Galenica Pharmaceuticals, Inc. | Semi-synthetic saponin analogs with carrier and immune stimulatory activities for DNA and RNA vaccines |
| WO2019011914A1 (en) * | 2017-07-11 | 2019-01-17 | Freie Universität Berlin | NOVEL USES OF SAPONIN AND METHOD FOR ITS ISOLATION |
Non-Patent Citations (6)
| Title |
|---|
| BIOMEDICINES, vol. 5(14):1-25, JPN6025032636, 2017, ISSN: 0005875204 * |
| BIOMEDICINES, vol. 5(4):Article ID 14, JPN6023048558, 29 March 2017 (2017-03-29), ISSN: 0005875206 * |
| CURRENT PHARMACEUTICAL DESIGN, vol. 20(42):6584-6643, JPN6023048556, 22 October 2014 (2014-10-22), ISSN: 0005875208 * |
| MOLECULAR ONCOLOGY, vol. 11(11):1527-1543, JPN6023048557, 15 September 2017 (2017-09-15), ISSN: 0005875207 * |
| MOLECULAR THERAPY: NUCLEIC ACIDS, vol. 14:67-79, JPN6025032638, 2019, ISSN: 0005875205 * |
| PHARMACEUTICAL BIOLOGY, vol. 40(4):253-262, JPN6026022425, 2002, ISSN: 0005875203 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4591938A3 (en) | 2025-11-05 |
| WO2022265493A1 (en) | 2022-12-22 |
| EP4355369C0 (en) | 2025-06-18 |
| US20240307545A1 (en) | 2024-09-19 |
| EP4355369A1 (en) | 2024-04-24 |
| EP4355369B1 (en) | 2025-06-18 |
| EP4591938A2 (en) | 2025-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4171641B1 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| EP4355369B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2022055351A1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| WO2021261998A1 (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| WO2022055352A1 (en) | Semicarbazone-based saponin conjugate | |
| EP4210760B1 (en) | Conjugate of saponin, oligonucleotide and galnac | |
| JP7862331B2 (ja) | GalNAc-オリゴヌクレオチドコンジュゲート及びサポニンの治療用配合物、及びその使用 | |
| AU2021295358B2 (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac-oligonucleotide conjugate | |
| HK40124033A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40110483B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| AU2021339332A1 (en) | Conjugate of saponin, oligonucleotide and GalNAc | |
| HK40091234A (en) | Conjugate of saponin, oligonucleotide and galnac | |
| HK40091234B (en) | Conjugate of saponin, oligonucleotide and galnac | |
| CN117881427A (zh) | 皂苷、寡核苷酸和galnac的缀合物 | |
| HK40116734A (en) | Conjugate of galnac and saponin, therapeutic composition comprising said conjugate and a galnac oligonucleotide conjugate | |
| HK40128805A (en) | Therapeutic combination of galnac-oligonucleotide conjugate and saponin, and uses thereof | |
| HK40129944A (zh) | Galnac和皂苷的缀合物、包含所述缀合物和galnac-寡核苷酸缀合物的治疗性组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250305 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250305 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260602 |